Related references
Note: Only part of the references are listed.The bone marrow microenvironment as a sanctuary for minimal residual disease in CML
Rajesh R. Nair et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Galectin-3: A novel substrate for c-Abl kinase
Vitaly Balan et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2010)
GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death
Matthew J. Streetly et al.
BLOOD (2010)
Wnt/Ca2+/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr-Abl
Mark A. Gregory et al.
CANCER CELL (2010)
Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment
M. Takeuchi et al.
CELL DEATH AND DIFFERENTIATION (2010)
c-Abl and Arg tyrosine kinases regulate lysosomal degradation of the oncoprotein Galectin-3
X. Li et al.
CELL DEATH AND DIFFERENTIATION (2010)
Emerging drugs for chronic myeloid leukemia
Daniela Cilloni et al.
EXPERT OPINION ON EMERGING DRUGS (2010)
Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis
Fabrizio Vianello et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Chronic myeloid leukemia: mechanisms of blastic transformation
Danilo Perrotti et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Osteoclasts are involved in the maintenance of dormant leukemic cells
Asumi Yokota et al.
LEUKEMIA RESEARCH (2010)
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
Douglas W. McMillin et al.
NATURE MEDICINE (2010)
Resistance to Imatinib: Mutations and Beyond
Paul La Rosee et al.
SEMINARS IN HEMATOLOGY (2010)
Regulation of Prostate Cancer Progression by Galectin-3
Yi Wang et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Advances in the biology and therapy of patients with chronic myeloid leukaemia
Elias Jabbour et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance
Kumudha Balakrishnan et al.
BLOOD (2009)
Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
Dragana Milojkovic et al.
CLINICAL CANCER RESEARCH (2009)
Involvement of BH3-only proteins in hematologic malignancies
Junya Kuroda et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Advances in treatment of chronic myelogenous leukemia - new treatment options with tyrosine kinase inhibitors
Fabio P. S. Santos et al.
LEUKEMIA & LYMPHOMA (2009)
Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance
D. Bixby et al.
Hematology-American Society of Hematology Education Program (2009)
Environment-mediated drug resistance: a major contributor to minimal residual disease
Mark B. Meads et al.
NATURE REVIEWS CANCER (2009)
Increased Serum 90K and Galectin-3 Expression Are Associated with Advanced Stage and a Worse Prognosis in Diffuse Large B-Cell Lymphomas
Seok Jin Kim et al.
ACTA HAEMATOLOGICA (2008)
Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
Neil P. Shah et al.
CANCER CELL (2008)
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Ellen Weisberg et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
J. A. McCubrey et al.
LEUKEMIA (2008)
Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells
Angela Colmone et al.
SCIENCE (2008)
Galectins in the tumor endothelium: opportunities for combined cancer therapy
Victor L. J. L. Thijssen et al.
BLOOD (2007)
Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation
Soraya Wuilleme-Toumi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia
Richard T. Williams et al.
GENES & DEVELOPMENT (2007)
Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure
Crystal L. Jackson et al.
GLYCOBIOLOGY (2007)
The role of galectin-3 in cancer drug resistance
Tomoharu Fukumori et al.
DRUG RESISTANCE UPDATES (2007)
Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn
Takuo Ito et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT 5 pathway activation
Ying Wang et al.
BLOOD (2007)
Galectin-3 in apoptosis, a novel therapeutic target
Pratima Nangia-Makker et al.
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES (2007)
Galectins as modulators of tumor progression in head and neck squamous cell carcinomas
Sven Saussez et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2007)
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia
J. Kuroda et al.
CELL DEATH AND DIFFERENTIATION (2007)
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (vol 103, pg 14907, 2006)
Junya Kuroda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
Junya Kuroda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia
S Soverini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
YG Hu et al.
NATURE GENETICS (2004)
Detection of t(14;18) in follicular lymphoma by dual-color fluorescence in situ hybridization on paraffin-embedded tissue sections
Y Matsumoto et al.
CANCER GENETICS AND CYTOGENETICS (2004)
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
NJ Donato et al.
CANCER RESEARCH (2004)
Alterations in galectin-3 expression and distribution correlate with breast cancer progression - Functional analysis of galectin-3 in breast epithelial-endothefial interactions
MPV Shekhar et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Animal models of chronic myelogenous leukemia
RL Ilaria
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2004)
p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa
A Villunger et al.
SCIENCE (2003)
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate
J Kuroda et al.
BLOOD (2003)
The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model
RB Ren
ONCOGENE (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and γ-irradiation
JS Damiano et al.
LEUKEMIA (2001)
Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis
P Matarrese et al.
FEBS LETTERS (2000)
Share Paper
